

---

# Guidance for Industry

## Q8(R2) Pharmaceutical Development

U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)

November 2009  
ICH

Revision 2

# Guidance for Industry

## Q8(R2) Pharmaceutical Development

*Additional copies are available from:*

*Office of Communications  
Division of Drug Information, WO51, Room 2201  
10903 New Hampshire Ave.  
Silver Spring, MD 20993  
Phone: 301-796-3400; Fax: 301-847-8714  
druginfo@fda.hhs.gov*

<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

*Office of Communication, Outreach and Development, HFM-40  
Center for Biologics Evaluation and Research  
Food and Drug Administration  
1401 Rockville Pike, Rockville, MD 20852-1448  
(Tel) 800-835-4709 or 301-827-1800*

<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**November 2009  
ICH**

**Revision 2**

## TABLE OF CONTENTS

### PHARMACEUTICAL DEVELOPMENT — PARENT GUIDANCE

<b>I.</b>	<b>INTRODUCTION (1, 1.1)</b> .....	<b>1</b>
<b>II.</b>	<b>PHARMACEUTICAL DEVELOPMENT (2)</b> .....	<b>2</b>
<b>A.</b>	<b>Components of the Drug Product (2.1)</b> .....	<b>4</b>
	1. <i>Drug Substance (2.1.1)</i> .....	4
	2. <i>Excipients (2.1.2)</i> .....	4
<b>B.</b>	<b>Drug Product (2.2)</b> .....	<b>5</b>
	1. <i>Formulation Development (2.2.1)</i> .....	5
	2. <i>Overages (2.2.2)</i> .....	5
	3. <i>Physicochemical and Biological Properties (2.2.3)</i> .....	6
<b>C.</b>	<b>Manufacturing Process Development (2.3)</b> .....	<b>6</b>
<b>D.</b>	<b>Container Closure System (2.4)</b> .....	<b>7</b>
<b>E.</b>	<b>Microbiological Attributes (2.5)</b> .....	<b>7</b>
<b>F.</b>	<b>Compatibility (2.6)</b> .....	<b>8</b>
<b>III.</b>	<b>GLOSSARY (3)</b> .....	<b>9</b>

### PHARMACEUTICAL DEVELOPMENT — ANNEX

<b>1.</b>	<b>INTRODUCTION (1)</b> .....	<b>10</b>
<b>II.</b>	<b>ELEMENTS OF PHARMACEUTICAL DEVELOPMENT (2)</b> .....	<b>11</b>
<b>A.</b>	<b>Quality Target Product Profile (2.1)</b> .....	<b>11</b>
<b>B.</b>	<b>Critical Quality Attributes (2.2)</b> .....	<b>12</b>
<b>C.</b>	<b>Risk Assessment: Linking Material Attributes and Process Parameters to Drug Product CQAs (2.3)</b> .....	<b>12</b>
<b>D.</b>	<b>Design Space (2.4)</b> .....	<b>13</b>
	1. <i>Selection of Variables (2.4.1)</i> .....	13
	2. <i>Describing a Design Space in a Submission (2.4.2)</i> .....	13
	3. <i>Unit Operation Design Space(s) (2.4.3)</i> .....	13
	4. <i>Relationship of Design Space to Scale and Equipment (2.4.4)</i> .....	14
	5. <i>Design Space Versus Proven Acceptable Ranges (2.4.5)</i> .....	14
	6. <i>Design Space and Edge of Failure (2.4.6)</i> .....	14
<b>E.</b>	<b>Control Strategy (2.5)</b> .....	<b>14</b>
<b>F.</b>	<b>Product Lifecycle Management and Continual Improvement (2.6)</b> .....	<b>15</b>
<b>III.</b>	<b>SUBMISSION OF PHARMACEUTICAL DEVELOPMENT AND RELATED INFORMATION IN COMMON TECHNICAL DOCUMENT (CTD) FORMAT (3)</b> .....	<b>16</b>

<b>A.</b>	<b>Quality Risk Management and Product and Process Development (3.1)</b> .....	<b>16</b>
<b>B.</b>	<b>Design Space (3.2)</b> .....	<b>16</b>
<b>C.</b>	<b>Control Strategy (3.3)</b> .....	<b>16</b>
<b>D.</b>	<b>Drug Substance Related Information (3.4)</b> .....	<b>17</b>
<b>IV.</b>	<b>GLOSSARY (4)</b> .....	<b>18</b>
	<b>Appendix 1. Differing Approaches to Pharmaceutical Development</b> .....	<b>19</b>
	<b>Appendix 2. Illustrative Examples</b> .....	<b>20</b>

## Guidance for Industry<sup>1</sup>

### Q8(R2) Pharmaceutical Development

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

This guidance is a revision of the ICH guidance *Q8 Pharmaceutical Development* (Q8 parent guidance) that published in May 2006. In June 2009, the Q8 parent guidance was revised to add an annex, which provides further clarification of the key concepts outlined in the May 2006 guidance and describes the principles of quality by design (QbD). The Q8(R1) document issued in June 2009 includes the Q8 parent guidance and the annex. This second revision, Q8(R2), provides corrected captions for figures 2a and 2b in Appendix 2, section C.

#### I. INTRODUCTION (1, 1.1)<sup>2</sup>

The Q8 parent guidance describes the suggested contents for the 3.2.P.2 (Pharmaceutical Development) section of a regulatory submission in the ICH M4 Common Technical Document (CTD) format.

The Pharmaceutical Development section provides an opportunity to present the knowledge gained through the application of scientific approaches and quality risk management (for

---

<sup>1</sup> This guidance was developed within the Expert Working Group (Quality) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and has been subject to consultation by the regulatory parties, in accordance with the ICH process. This guidance includes an annex to *Q8 Pharmaceutical Development* (the Q8 parent guidance). The annex has been endorsed by the ICH Steering Committee at *Step 4* of the ICH process, November 2008. At *Step 4* of the process, the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan, and the United States. Following the addition of the annex to the Q8 parent guidance, ICH recoded the guidance Q8(R1). In August 2009, ICH issued Q8(R2) with corrected captions for figures 2a and 2b in Appendix 2, section C.

<sup>2</sup> Arabic numbers reflect the organizational breakdown of the Q8 parent guidance endorsed by the ICH Steering Committee at *Step 4* of the ICH process, November 2005.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.